Comparative Pharmacology
Head-to-head clinical analysis: ELIXICON versus PHYLLOCONTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELIXICON versus PHYLLOCONTIN.
ELIXICON vs PHYLLOCONTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Theophylline is a xanthine derivative that inhibits phosphodiesterase, leading to increased intracellular cyclic AMP levels. It also acts as a nonselective adenosine receptor antagonist, resulting in bronchodilation and anti-inflammatory effects.
Sustained-release theophylline; nonselective phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase activator. Bronchodilation via relaxation of bronchial smooth muscle; also reduces airway hyperresponsiveness and inflammation.
400 mg orally every 6 hours or 600 mg orally every 8 hours; extended-release: 600-1200 mg orally every 12 hours.
For chronic obstructive pulmonary disease and asthma: initial dose 225 mg orally twice daily; may increase to 450 mg twice daily. Based on theophylline, target serum concentration 5-15 mcg/mL.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours in adults; 3-4 hours in children; prolonged in hepatic impairment or congestive heart failure. Context: dosing interval adjustment required in these conditions.
Terminal elimination half-life: 3-8 hours in non-smoking adults; reduced to 1.5-5 hours in smokers; prolonged to 10-30 hours in heart failure or hepatic cirrhosis.
Renal: 50% unchanged; hepatic metabolism to 3-methylxanthine, theophylline, etc. Biliary/fecal: minimal.
Renal: approximately 10% unchanged; hepatic metabolism accounts for ~90% of clearance; metabolites eliminated renally.
Category C
Category C
Xanthine Bronchodilator
Xanthine Bronchodilator